profit from every €100 of sales.
€0€100
Fagron NV
€24.20-0.62% today
+13.6% since Dec 22, 25
1-year low €21.001-year high €25.25
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay €19.51 for every €1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Fagron NV sold, what it kept, and what it did with the cash.
Sales went from €684 million in 2022 to €952 million in 2025, with €91.0 million of profit last year.
SalesProfit
Fagron NV handed back 24% of the cash it generated last year.
€26M
Free cash flow 2025€125M
Bought back its own shares€4M
Paid as dividends€26M
Cash vs. debt€185M vs. €468M
Fagron NV vs. similar companies
Fagron NV grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
| Fagron NV | 19.5× · Fair price | ||
 Merck KGaA | 24.7× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Fagron NV's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 684 | 763 | 872 | 952 | |
| 286 | 333 | 396 | 432 | |
| 101 | 113 | 134 | 147 | |
| 130 | 134 | 158 | 181 | |
| 70 | 71 | 81 | 91 | |
| 0.96 | 0.97 | 1.10 | 1.24 | |
| 41.8% | 43.6% | 45.4% | 45.4% | |
| 14.8% | 14.8% | 15.4% | 15.5% | |
| 10.2% | 9.2% | 9.2% | 9.6% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 971 | 1,007 | 1,084 | 1,243 |
| Cash | 125 | 133 | 115 | 185 |
| Total debt | 399 | 367 | 386 | 468 |
| Total liabilities | 560 | 539 | 578 | 687 |
| 405 | 464 | 501 | 552 | |
| 73 | 73 | 73 | 73 | |
| 9.7% | 9.5% | 10.8% | 10.6% | |
| 17.2% | 15.2% | 16.1% | 16.5% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 109 | 125 | 110 | 155 | |
| 18 | 38 | 41 | 31 | |
| 91 | 86 | 69 | 125 | |
| Dividends paid | 15 | 18 | 21 | 26 |
| 0 | 2 | 3 | 4 | |
| 2 | 2 | 1 | 1 |
Valuation
- 19.5×
- –
- 2.19
- 3.2×
- 1.9×
- 14.2×
- 11.4×
- 7.0%
- 5.1%
- 1.5%
Profitability
- 45.4%
- 15.5%
- 9.6%
- –
- 10.1%
- 9.6%
- –
- –
- –
- –
Growth
- +11.7%
- +8.9%
- –
- –
- +0.1%
Financial health
- 1.6×
- 0.85
- –
- 6.9×
- 2.11
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 30%of 952
Top 34%of 883
Top 32%of 576
Top 49%of 870
Top 13%of 985
1.5%of the share price, paid each year
On $1,000 invested$15a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
28.6% of its profit
Room to growStretchedMore than it earns: 20.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
54No pass
Philip Fisher
57No pass
Peter Lynch
40No pass
Joel Greenblatt
35No pass
Charlie Munger
47No pass
Terry Smith
50No pass
Questions about Fagron NV
Is Fagron NV a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fagron NV AI analysis
What does Fagron NV do?
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. It is in Drug Manufacturers - Specialty & Generic, based in Nazareth, Belgium, with 4,193 employees.
Does Fagron NV pay a dividend?
Yes. At today's price the dividend is 1.5% a year, about 29% of its yearly profit. In 2025 it paid out €26.0 million in dividends.
Is Fagron NV stock halal?
Yes. Fagron NV passes our halal screen: its business is permitted and its debt is 26% of its market value, under the 30% limit. How we check
Who are Fagron NV's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Fagron NV's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.